Clinical Trial Update: Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating Cu64-DOTA-trastuzumab PET imaging and biomarkers to predict response to neoadjuvant trastuzumab plus pertuzumab in HER2-positive…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Stage Iiia Breast Cancer
• Stage Iiib Breast Cancer
• Stage Iiic Breast Cancer

Drugs mentioned

• Cu64-DOTA-trastuzumab (Cu64-DOTA-trastuzumab)
• Pertuzumab (pertuzumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: City of Hope Medical Center | Conditions: HER2 Positive Breast Carcinoma, Stage IIIA Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-03-09